星空体育官方入口网站网址大全-登录入口官网

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2024-05-28 146707e2m20(暂无昵称) 来自西藏

投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛

28 0

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2023-10-19 1224e2e7m99(暂无昵称) 来自江苏省

审稿速度:2.0
偏重的研究方向：肿瘤
经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！

63 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2024-04-05 1240a43am62暂无昵称来自重庆

请问这个杂志接收到proof需要多久，快3周了还还消息。

32 0

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2023-12-26 ms8000000049838423 来自北京

偏重的研究方向：基础肿瘤
经验分享：2023.10.13 submitted
2023.10.22 Under Review
2023.11.8 major revise
2023.12.17 resubmitted
2023.12.18 accept

53 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2023-11-04 WX631576466 来自广西

我有endnotes 格式，可以无偿查重，需要找我

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2024-02-28 ms7000000196593357 来自江苏省

审稿速度:1.0 | 投稿命中率:95.0
经验分享：挺不错的期刊

51 0

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2022-08-29 ms2000000713462597

审稿速度:1.0 | 投稿命中率:25.0
经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%

73 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2023-02-20 咪小宝来自安徽省

审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤
经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业

83 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2023-03-16 ms1000002022682898 来自广西

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：药理学;肿瘤;天然产物
经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。

77 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2207002, encodeId=a23c220e0021c, content=投稿前都喊改这个格式那个格式，一个杂志一个格式，能不能投稿同意接受再改格式嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1f195138876, createdName=146707e2m20(暂无昵称), createdTime=Tue May 28 12:31:31 CST 2024, time=2024-05-28, status=1, ipAttribution=西藏), GetPortalCommentsPageByObjectIdResponse(id=2163690, encodeId=4e002163690d5, content=审稿速度:2.0 偏重的研究方向：肿瘤 经验分享：一个多月的Under Review，啥意思？表示在则责任编辑手里，还是已经送外审？期间状态一直没变。好着急呀！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a052321390, createdName=1224e2e7m99(暂无昵称), createdTime=Thu Oct 19 11:02:46 CST 2023, time=2023-10-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197033, encodeId=f3ba219e0334f, content=请问这个杂志接收到proof需要多久，快3周了还还消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200826/bbc61687fab64e71b236e41ce01103f8/8663b492335744f1b226bbfd943715de.jpg, createdBy=a4622456608, createdName=1240a43am62暂无昵称, createdTime=Fri Apr 05 12:47:32 CST 2024, time=2024-04-05, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2177313, encodeId=30ab21e731310, content=偏重的研究方向：基础肿瘤 经验分享：2023.10.13 submitted 2023.10.22 Under Review 2023.11.8 major revise 2023.12.17 resubmitted 2023.12.18 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f556398226, createdName=ms8000000049838423, createdTime=Tue Dec 26 16:08:06 CST 2023, time=2023-12-26, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166694, encodeId=0696216669412, content=我有endnotes 格式，可以无偿查重，需要找我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230615/d755758c7e4e45b2860dd0db9a9c8a5f/d51b884347bd432b8ceba4bc8728fb21.jpg, createdBy=41b65550607, createdName=WX631576466, createdTime=Sat Nov 04 21:19:43 CST 2023, time=2023-11-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2189956, encodeId=b196218995615, content=审稿速度:1.0 | 投稿命中率:95.0 经验分享：挺不错的期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cb69091327, createdName=ms7000000196593357, createdTime=Wed Feb 28 19:37:23 CST 2024, time=2024-02-28, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1241867, encodeId=ffff124186ecf, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：medical oncology 08.22投稿，纯生信，一周后被拒，理由评分不高，整体拒稿率达到80%, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Mon Aug 29 17:04:58 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2115612, encodeId=902621156126d, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：第一篇，6.20-8.18出版第二篇，11.21-2.20接收总的来说，我觉得这个杂志速度挺快的，审稿专家提的问题也很专业, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d015545609, createdName=咪小宝, createdTime=Mon Feb 20 23:27:20 CST 2023, time=2023-02-20, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2119874, encodeId=38f021198e4a6, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：药理学;肿瘤;天然产物 经验分享：3月1日submitted，3月3日under review，3月13日minor revise，3月15日修回，3月16日accept。快到不敢相信。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=253b6502588, createdName=ms1000002022682898, createdTime=Thu Mar 16 08:29:38 CST 2023, time=2023-03-16, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1226850, encodeId=4c41122685008, content=没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87858206415, createdName=ms7000001655187333, createdTime=Thu Jun 16 17:20:09 CST 2022, time=2022-06-16, status=1, ipAttribution=)]

2022-06-16 ms7000001655187333

没有找到medical oncology 的参考文献引用格式endnote的ens文件，有朋友可以提供一下吗

99 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务